Synchron has raised a $200 million Series D financing round to accelerate the commercialization of its Stentrode brain-computer interface platform and advance the development of a next-generation neural interface system. The round was led by Double Point Ventures, with participation from existing backers ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New investors included the Australian National Reconstruction Fund, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, and IQT. This financing brings Synchron’s total funding to $345 million.
The company, headquartered in New York with an engineering hub in San Diego, is focused on restoring digital communication and control for people with paralysis through a minimally invasive approach to brain-computer interfacing. And the company’s Stentrode platform is the first endovascular brain-computer interface designed to enable thought-driven control of digital devices without open-brain surgery.
The system is implanted via a catheter procedure that positions the interface alongside the motor cortex within blood vessels. Neural signals are then recorded and transmitted wirelessly, enabling hands-free interaction with consumer technology. Synchron has implanted the Stentrode in ten patients across clinical trials in the United States and Australia.
Synchron was also the first BCI company to integrate Apple’s BCI-human interface device protocol, allowing brain signals to directly control iPhone, iPad and Vision Pro through Apple’s Switch Control accessibility framework.
The company plans to use the Series D funding to expand its Cognitive AI division in New York, which is training models to decode brain signals into digital commands in real time. And its San Diego team advances hardware engineering for future high-channel interfaces. The capital will also support pivotal trials and preparation for commercial launch, along with additional hiring across engineering and neuroscience.
KEY QUOTES:
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercializing the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
Tom Oxley, CEO and Founder, Synchron
“Synchron is building the first truly scalable, minimally invasive brain-computer interface that can be deployed in everyday healthcare. Its fusion of neurovascular access, breakthrough device engineering, and adaptive AI marks a fundamental step toward restoring digital agency to people with paralysis.”
Campbell Murray, MD, Co-Founder and Managing Partner, Double Point Ventures
“Synchron’s work is expanding the frontier of what’s possible between the human brain and technology. This next phase brings us closer to a future where brain interfaces can potentially unlock entirely new dimensions for healthcare.”
Dr. Bob Langer, Executive Chairman, T.Rx Capital
